Evidence on VBID's effectiveness

Health Affairs' Jeff Byers welcomes Mark Fendrick of The University of Michigan's Center for Value-Based Insurance Design (VBID) to discuss the recent announcement from CMS that the Medicare Advantage VBID model would be ending after 2025, and what the future holds for VBID moving forward with the new Trump administration.

Check out a recently released Health Policy brief from Nathaniel Tran and Gilbert Gonzales exploring LGBTQI+ policies.

Join Health Affairs on February 25 for an exclusive Insider virtual event featuring Stacie Dusetzina and Laura Tollen discussing HHS’s announcement of the 15 additional drugs selected for Medicare drug price negotiations, including weight-loss drugs such as Ozempic and Wegovy.

Also, join a live recording of A Health Podyssey on March 12 featuring Rob Lott and Yashaswini Singh discussing her recent paper on the effect of private equity on physician turnover.  Register for the live taping here.

Related Articles:

• The End Of The MA Value-Based Insurance Design Model: What Next? (Health Affairs Forefront)
• V-BID X: Creating A Value-Based Insurance Design Plan For The Exchange Market (Health Affairs Forefront)
• Medicare Advantage Value-Based Insurance Design (VBID) Model to End after Calendar Year 2025 (CMS)